Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 25, 2026, 8:10 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 7,083 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Austin, Texas Clear all
Completed Phase 3 Interventional Results available

A Study in Adults With Type 1 Diabetes

NCT01421147
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
LY2963016, Lantus, Insulin Lispro
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
21
States / cities
Birmingham, Alabama • Hollywood, Florida • New Port Richey, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2014 · Synced Jul 25, 2026, 8:10 AM EDT
Recruiting Not applicable Interventional

GATEWAY: Safety Evaluation of the MiniMed™ NMX8-AID System in Children and Adults Living With Diabetes

NCT07228117
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MiniMed™ NMX8-AID System with DS5™/Simplera Sync™
Device
Lead sponsor
Medtronic MiniMed, Inc.
Industry
Eligibility
7 Years to 85 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
33
States / cities
Little Rock, Arkansas • Escondido, California • Goleta, California + 29 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Study of a Combination Vaccine Comprised of Different Recombinant Spike Antigen Levels of a Matrix-M Adjuvanted Recombinant COVID-19 Vaccine and High-Dose Inactivated Influenza Vaccine in Adult Participants 50 Years of Age and Older

NCT06695117
View directory record Official record
Conditions
COVID-19 Immunization, Influenza Immunization
Interventions
IIV-HD, rC19 (dose 1), IIV-HD + rC19 (dose 1), IIV-HD + rC19 (dose 2), IIV-HD + rC19 (dose 3), IIV-HD + rC19 (dose 4), Placebo (0.9% NaCl)
Biological · Other
Lead sponsor
Sanofi
Industry
Eligibility
50 Years and older
Enrollment
980 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
12
States / cities
Birmingham, Alabama • Huntsville, Alabama • Tucson, Arizona + 9 more
Source: ClinicalTrials.gov public record
Updated May 4, 2026 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of KPI-121 in Subjects With Postsurgical Inflammation and Pain

NCT02793817
View directory record Official record
Conditions
Post Surgical Ocular Inflammation and Pain
Interventions
KPI-121 1% Ophthalmic Suspension dosed BID, Vehicle of KPI-121 Ophthalmic Suspension dosed BID
Drug
Lead sponsor
Kala Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
520 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
35
States / cities
Chandler, Arizona • Phoenix, Arizona • Artesia, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 15, 2020 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)

NCT05117489
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis (NASH)
Interventions
Miricorilant 150 mg, Miricorilant 100 mg, Miricorilant 50 mg, Miricorilant 10 mg
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
9
States / cities
Chandler, Arizona • Tucson, Arizona • Panorama City, California + 6 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2024 · Synced Jul 25, 2026, 8:10 AM EDT
Active, not recruiting Phase 3 Interventional

A Study of Brepocitinib in Adults With Active, Non-Infectious, Non-Anterior Uveitis

NCT06431373
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Uveitis
Interventions
Brepocitinib PO QD, Placebo PO QD
Drug
Lead sponsor
Priovant Therapeutics, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
371 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
53
States / cities
Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Drug Levels of Deucravacitinib From Tablets After Oral Administration in Healthy Participants

NCT04949269
View directory record Official record
Conditions
Healthy Participants
Interventions
Deucravacitinib, Famotidine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
2
States / cities
Miami, Florida • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2022 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional

Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain

NCT00259922
View directory record Official record
Conditions
Bowel Dysfunction, Constipation
Interventions
Placebo, Alvimopan, Alviompan
Drug
Lead sponsor
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
485 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
119
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 104 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2015 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Not applicable Interventional Results available

Glycemic Control and Treatment Satisfaction Using Finesse Versus Pen for Initiating Bolus Insulin Dosing in Type 2 Diabetes Patients

NCT02542631
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Bolus Insulin Patch (Calibra Finesse), Insulin Pen (Novo-Nordisk FlexPen®)
Device
Lead sponsor
Calibra Medical, Inc.
Industry
Eligibility
22 Years to 75 Years
Enrollment
278 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
35
States / cities
Phoenix, Arizona • Escondido, California • Greenbrae, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Cellular and Immunologic Changes in the Skin of Subjects Receiving PH-10

NCT02322086
View directory record Official record
Conditions
Psoriasis
Interventions
Topical Rose Bengal, 0.005%
Drug
Lead sponsor
Provectus Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
3
States / cities
Miami, Florida • Chapel Hill, North Carolina • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jul 25, 2026, 8:10 AM EDT
Active, not recruiting Phase 1 Interventional

Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)

NCT04185883
View directory record Official record
Conditions
Advanced Solid Tumors, Kirsten Rat Sarcoma (KRAS) pG12C Mutation
Interventions
Sotorasib, Trametinib, RMC-4630, Afatinib, Pembrolizumab, Panitumumab, Carboplatin, pemetrexed, docetaxel, paclitaxel, Atezolizumab, Palbociclib, MVASI® (bevacizumab-awwb), TNO155, IV Chemotherapy (Regimen 1), IV Chemotherapy (Regimen 2), BI 1701963, AMG 404, Everolimus
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
610 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
55
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 42 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2025 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Long-term Safety and Efficacy Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis (ADjoin)

NCT04392154
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Lebrikizumab
Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
12 Years and older
Enrollment
1,153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
160
States / cities
Anniston, Alabama • Birmingham, Alabama • Scottsdale, Arizona + 124 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2025 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 2 Interventional Results available

To Evaluate the Pharmacodynamics, Safety, and Pharmacokinetics of Pazopanib Drops in Adult Subjects With Neovascular AMD

NCT00612456
View directory record Official record
Conditions
Macular Degeneration
Interventions
Pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
16
States / cities
Tucson, Arizona • Beverly Hills, California • Pasadena, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2017 · Synced Jul 25, 2026, 8:10 AM EDT
Terminated No phase listed Observational Results available

ST Segment Detection Study

NCT00930969
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
ICD
Device
Lead sponsor
Medtronic Cardiac Rhythm and Heart Failure
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
17
States / cities
Anchorage, Alaska • Brandon, Florida • Orlando, Florida + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 17, 2019 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

A Phase 3b Study of Erythropoietin Drugs Using a Specified Dosing Algorithm in Patients With Chronic Kidney Disease on Hemodialysis

NCT02504294
View directory record Official record
Conditions
Chronic Kidney Disease (CKD)
Interventions
Epoetin Hospira Arm, Standard of Care Arm, IV Iron
Biological · Other · Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
42
States / cities
Chula Vista, California • Poway, California • Rancho Bernardo, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Lurasidone HCl - A Long Term Safety Phase 3 Study of Patients With Clinically Stable Schizophrenia

NCT00641745
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
Lurasidone HCl, Risperidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
629 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
41
States / cities
Little Rock, Arkansas • Anaheim, California • Cerritos, California + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2015 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Pivotal Study to Evaluate Safety and Immunogenicity of a Live-Attenuated Chikungunya Virus Vaccine Candidate in Adults

NCT04546724
View directory record Official record
Conditions
Chikungunya Virus Infection
Interventions
VLA1553, Placebo
Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
18 Years and older
Enrollment
4,128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
44
States / cities
Chandler, Arizona • Phoenix, Arizona • Tempe, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial

NCT00799903
View directory record Official record
Conditions
Atherosclerosis
Interventions
Darapladib, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
15,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
155
States / cities
Birmingham, Alabama • Huntsville, Alabama • Anchorage, Alaska + 132 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2017 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Not applicable Interventional Results available

Single Embryo TrAnsfeR of Euploid Embryo

NCT02268786
View directory record Official record
Conditions
Infertility, Aneuploidy
Interventions
Preimplantation Genetic Screening by NGS
Other
Lead sponsor
Illumina, Inc.
Industry
Eligibility
25 Years to 40 Years · Female only
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
28
States / cities
Tempe, Arizona • Encino, California • Laguna Niguel, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Jul 25, 2026, 8:10 AM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of ALKS 2680 in Adults With Narcolepsy Type 1

NCT07455383
View directory record Official record
Conditions
Narcolepsy Type 1
Interventions
ALKS 2680 Dose 1, ALKS 2680 Dose 2, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
18
States / cities
Cullman, Alabama • Los Angeles, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Mipomersen on Cardiac Repolarization Conducted in Healthy Subjects

NCT01090661
View directory record Official record
Conditions
Healthy
Interventions
mipomersen sodium, moxifloxacin hydrochloride (Avelox®), placebo
Drug
Lead sponsor
Kastle Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2016 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Web-Based Physical Activity Intervention in Improving Long Term Health in Children and Adolescents With Cancer

NCT03223753
View directory record Official record
Conditions
Carcinoma In Situ, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Educational Intervention, Internet-Based Intervention, Laboratory Biomarker Analysis, Medical Device Usage and Evaluation, Quality-of-Life Assessment, Questionnaire Administration
Other · Device
Lead sponsor
Children's Oncology Group
Network
Eligibility
8 Years to 16 Years
Enrollment
299 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
113
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 91 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2026 · Synced Jul 25, 2026, 8:10 AM EDT
Recruiting Phase 3 Interventional

A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years

NCT06810505
View directory record Official record
Conditions
Chronic Migraine
Interventions
Atogepant, Placebo for Atogepant
Drug
Lead sponsor
AbbVie
Industry
Eligibility
12 Years to 17 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
31
States / cities
Huntsville, Alabama • Fayetteville, Arkansas • Little Rock, Arkansas + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Jul 25, 2026, 8:10 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

NCT02787551
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Insulin glargine/lixisenatide fixed ratio combination, liraglutide, exenatide, exenatide extended-release, albiglutide, dulaglutide, Background therapy: Oral Anti-diabetic Drug (Metformin, Pioglitazone, SGLT2 inhibitor)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
74
States / cities
Birmingham, Alabama • Fountain Hills, Arizona • Phoenix, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2022 · Synced Jul 25, 2026, 8:10 AM EDT